A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Recent Share Price Surge

Key recent moves in Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals (APLS) has drawn investor attention after a sharp move in its share price over the past month, with the stock returning about 104% over that period.

See our latest analysis for Apellis Pharmaceuticals.

That sharp 103.6% 30 day share price return sits on top of a 54.9% 90 day gain and a 57.4% year to date move. The 1 year total shareholder return of 107.5% contrasts with weaker 3 year and 5 year total shareholder returns, suggesting momentum has recently strengthened after a tougher multi year stretch.

If this kind of sharp rerating in healthcare catches your eye, it may be worth widening your search with a curated set of 34 healthcare AI stocks.

With Apellis trading at US$40.69, close to a typical analyst price target yet showing a sizeable modelled intrinsic discount, the key question is whether the stock still trades below its true worth or whether the market is already pricing in future growth.

Most Popular Narrative: 14% Overvalued

Apellis closed at $40.69, while the most followed narrative sees fair value closer to $35.71, built using a 7.22% discount rate and detailed long term forecasts.

The recent FDA label expansion for EMPAVELI into rare kidney diseases (C3G and IC-MPGN), along with active plans to launch and pursue additional indications (FSGS and DGF), positions Apellis to access larger patient pools and accelerate long-term topline growth, driven by the increasing prevalence of rare and age-associated diseases. This is likely to result in higher future revenues and market diversification.

Read the complete narrative.

Want to see the full playbook behind that fair value? The narrative leans on specific revenue growth, margin expansion, and a rich future earnings multiple. The exact mix might surprise you.

Result: Fair Value of $35.71 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still watchpoints, including pressure from free drug programs and co pay funding gaps, as well as tougher competition that could cap pricing power and margins.

Find out about the key risks to this Apellis Pharmaceuticals narrative.

Another way to look at Apellis’ value

The first narrative leans heavily on earnings forecasts and a future P/E of about 34.9x in 2029 to argue Apellis is 14% overvalued at $40.69 versus a $35.71 fair value. Yet on today’s numbers, the P/S ratio of 5.2x sits well below the US Biotechs average of 11.2x and only slightly above a fair ratio of 4.7x. This points to a tighter valuation gap and a different balance between risk and opportunity, so which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Plenty of data points here point in different directions, so it makes sense to move quickly and test the story against your own expectations with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Apellis has sharpened your focus, do not stop here. A wider watchlist can reveal ideas you would regret missing later.

• Target income first by checking out 12 dividend fortresses that aim to combine higher yields with durable payouts.
• Hunt for value by reviewing screener containing 24 high quality undiscovered gems that pair strong fundamentals with lower investor attention.
• Prioritise resilience by using the 72 resilient stocks with low risk scores to highlight companies with more stable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com